Cryopreserved Leukopak Viability and Supplier Selection

Cryopreserved leukopaks are getting adopted fast for one simple reason. Fresh starting material creates supply chain risk.

Leukopak deliveries can be late, arrive outside temperature requirements, or miss a critical manufacturing window entirely. When that happens, teams do not just lose a leukopak. They lose staff time, reagents, a manufacturing slot, and sometimes patient scheduling flexibility.

Cryopreservation is one of the most practical ways to remove many of those failure points. But it only works if the leukopak performs the way your process needs it to perform after thaw.

That is why the two most important questions are linked.

What should post thaw viability and recovery look like?
And how do you pick a cryopreserved leukopak supplier that can consistently deliver it?

This guide answers both.

---

What is a cryopreserved leukopak

A leukopak is a concentrated collection of white blood cells collected by apheresis. A cryopreserved leukopak is that same product, processed and frozen under controlled conditions so it can be stored and shipped for later use.

Cryopreserved starting material is used to:

Support manufacturing scheduling
Enable centralized manufacturing
Reduce the risk of missed collection and transport windows
Improve planning for multi site trials

A key detail that is often missed is that cryopreservation is not just freezing cells. It is an end to end workflow that includes controlled handling before freezing, the freezing method itself, storage stability, validated shipping, and thaw and wash instructions.

The following are CGT Global mean percentages of cell populations for a single donor Leukopak prior to cryopreservation:

• T cells – 55%
• Monocytes – 27%
• B cells – 9%
• NK cells – 8%
• CD34+ stem cells – 0.1%
• Granulocytes – 2.4%

We do not guarantee the percentage of cell populations in a Leukopak, as they can vary from donor to donor.

Leukopaks are quickly Cryopreserved  after collection in a medium containing the cryoprotective agent CryoStorTM (10% DMSO) using a controlled rate freezer to ensure maximum viability.

For well controlled cryopreserved leukopak or leukapheresis material, post thaw viability is often in the 70% to 90%+ range, depending on protocol and the donor and how quickly it was cryopreserved after collection.

---

The “viability myth” and what actually matters post thaw

A common belief is that cryopreserved leukopaks automatically perform worse than fresh leukopaks.

The reality is more nuanced.

Yes, thawed immune cells can show lower immediate viability and may start slower in early expansion. But published research in cell therapy workflows shows that post thaw viability and recovery do not always predict the outcomes that actually matter most, such as expansion, phenotype consistency, and functional performance, especially when cryopreservation is well controlled.

In other words, the right question is not “is cryo worse.”

The right question is “is post thaw performance consistent enough for my process and clinical supply chain.”

That is a supplier and process control question, not a philosophical one.

---

Why post thaw viability matters more than most teams expect

Post thaw viability is not a vanity metric. It is often the first warning sign that the run will become expensive and unpredictable.

When viability and recovery drop, teams commonly see:

Lower starting yields
Slower or inconsistent expansion curves
Higher batch to batch variability
Lower editing or transduction performance
More deviations and investigations during GMP manufacturing

Even if viability is acceptable, function can shift depending on handling and the sensitivity of the cell subset.

Here is the blunt truth.

Your dose plan might be built on pre freeze counts. But your manufacturing reality is determined by what is viable and functional after thaw.

View our thawing protocol

---

What drives post thaw viability and recovery in cryopreserved leukopaks

There is no single lever. It is a chain. Break one link, and viability takes the hit.

1. Time and conditions before freezing

Cells degrade over time. Temperature control and time from collection to cryopreservation can meaningfully influence recovery and post thaw outcomes.

2. Cryoprotectant and formulation

Most cell cryopreservation workflows rely on a cryoprotectant such as DMSO. Concentration, exposure time, and formulation strategy influence osmotic stress and toxicity risk.

3. Controlled rate freezing and freeze curve control

Freeze too fast, and you increase intracellular ice formation. Freeze too slow, and you increase dehydration and osmotic stress. Controlled rate freezing and validated freeze curves are widely used to improve consistency.

4. Storage conditions and stability strategy

Liquid nitrogen storage with controlled inventory practices matters. Stability is not just “stored cold.” It is stored consistently.

5. Shipping and temperature excursion control

Cryogenic shipping can reduce timing risk, but only if the supplier uses validated dewars, temperature monitoring, and has an excursion response plan.

6. Thaw and wash method

Great cryopreserved material can still get damaged by inconsistent thawing or aggressive washing. A credible supplier provides clear thaw guidance and realistic expectations for recovery.

---

What “good” looks like for post thaw viability

There is no universal number that applies to every program. Different manufacturing workflows have different sensitivity to starting material.

But strong cryopreserved leukopak programs generally aim for:

High viability and recovery relative to pre freeze baseline
Minimal lot to lot variability across donors
Predictable behavior post thaw in the context of the intended process

And importantly, a supplier should be able to show you distributions over time, not just a single best case example.

A key takeaway from published CAR T manufacturing data is that while some immediate post thaw characteristics can shift, downstream outcomes and even clinical performance may remain comparable when cryopreservation is controlled and integrated into a standardized workflow.

---

The supplier selection checklist

How to choose a GMP cryopreserved leukopak partner

This is where teams get burned. They select based on counts and cost, then discover gaps when they need documentation, consistency, or operational reliability.

If you are choosing a GMP cryopreserved leukopak supplier, evaluate these areas.

1. Quality system maturity

Ask about:

Document control and training
Deviation handling and CAPA
Traceability and batch record practices
Change control expectations

If cryopreserved leukopaks support clinical programs, audit readiness is not optional.

2. Donor reliability and scheduling strategy

Cryopreservation helps solve a real supply chain problem because it allows collections to happen ahead of need, reducing the risk of donor no shows and urgent rescheduling. A supplier should be able to explain how they recruit, schedule, and backfill donors for clinical timelines.

3. Standardization of collection and processing

Ask what is standardized and what is not:

Apheresis parameters where possible
Processing timelines
Temperature controls
Acceptance criteria
Cryopreservation workflow and equipment controls

If a supplier cannot describe their control strategy, you will see variability.

4. Post thaw performance data, not just release specs

A serious supplier should be able to share:

Post thaw viability distributions across donors
Recovery expectations
Subset composition guidance if relevant
Storage rationale and stability approach
Thaw instructions and expected outcomes

You do not need perfection. You need predictability.

5. Shipping validation and cold chain competency

Ask about:

Validated cryogenic shippers
Temperature monitoring
Excursion response process
Chain of custody
Delivery reliability

Cryopreservation reduces supply chain risk, but only when logistics are treated like a controlled system.

6. Documentation package depth

For GMP cryopreserved leukopaks, you want consistency in documentation:

Certificate of analysis
Donor documentation
Chain of custody
Testing and release status
Deviation documentation when applicable

If documentation varies from lot to lot, your quality team ends up doing cleanup work.

Red flags that usually lead to downstream problems

Here is what typically causes pain later.

No clear cryopreservation method or controlled rate freezing details
No defined post thaw performance targets or distributions
Inconsistent documentation package from lot to lot
Weak shipping validation or vague excursion handling
Inability to provide historical consistency data

Those problems do not show up as small inconveniences. They show up as failed runs, missed timelines, or QA escalation.

---